Clinical Trial Update: The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD [Phase 3]

View source ↗

Summary

The MEASURE study, a Phase 3 trial evaluating MDX 1400 mg daily versus placebo in adults with ADHD, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• MDX

Snippet

Sponsor: Alcobra Ltd. | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Status: TERMINATED